Saturday, October 31, 2026

Lumen Technologies Stock Bearish Momentum With A 29% Drop In The Last 21 Sessions

ViaNews Editorial Team

February 17, 2023

Lumen Technologies Stock Bearish Momentum With A 29% Drop In The Last 21 Sessions

(VIANEWS) - Shares of Lumen Technologies (NYSE: LUMN) dropped by a staggering 29.95% in 21 sessions from $5.61 to $3.93 at 12:55 EST on Friday, after five sequential sessions in a row of losses. NYSE is falling 0.62% to $15,776.06, after three consecutive sessions in a row of losses.

Lumen Technologies's last close was $3.84, 74.59% below its 52-week high of $15.11.

About Lumen Technologies

Lumen Technologies, Inc., a facilities-based technology and communications company, provides various integrated products and services under the Lumen, Quantum Fiber, and CenturyLink brands to business and residential customers in the United States and internationally. The company operates in two segments, Business and Mass Markets. It offers compute and application services, such as cloud services, IT solutions, unified communication and collaboration solutions, colocation and data center services, content delivery services, and managed security services; and IP and data services, including VPN data network, Ethernet, internet protocol (IP), and voice over internet protocol. The company also provides fiber infrastructure services comprising high bandwidth optical wavelength networks; and unlit optical fiber and related professional services. In addition, it offers voice and other services, including private line services, a direct circuit or channel specifically dedicated for connecting two or more organizational sites; a portfolio of traditional time division multiplexing voice services; and synchronous optical network-based Ethernet, legacy data hosting services, and conferencing services. As of December 31, 2021, the company served approximately 4.5 million broadband subscribers. The company was formerly known as CenturyLink, Inc. and changed its name to Lumen Technologies, Inc. in September 2020. Lumen Technologies, Inc. was incorporated in 1968 and is headquartered in Monroe, Louisiana.

Earnings Per Share

As for profitability, Lumen Technologies has a trailing twelve months EPS of $-0.709.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.68%.

Moving Average

Lumen Technologies's worth is way under its 50-day moving average of $11.33 and way below its 200-day moving average of $11.96.

Volume

Today's last reported volume for Lumen Technologies is 9499126 which is 67.97% below its average volume of 26879600.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Lumen Technologies's stock is considered to be overbought (>=80).

Revenue Growth

Year-on-year quarterly revenue growth declined by 5.4%, now sitting on 19.69B for the twelve trailing months.

More news about Lumen Technologies (LUMN).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com